Novo Nordisk's Wegovy Goes Oral: Affordable 1.5 mg Pill Expands U.S. Access

Novo Nordisk starts selling a 1.5 mg Wegovy pill at $149/month in the U.S., expanding access to obesity treatment as the 4 mg price updates.

Overview

A summary of the key points of this story verified across multiple sources.

Novo Nordisk has launched a daily Wegovy pill at 1.5 mg for self-paying patients in the United States, marketed as the first affordable oral option for obesity treatment.

The price for the 4 mg Wegovy medication will remain constant until April 15, after which it will rise to $199.

The FDA approved the daily pill version in December, enabling oral administration of semaglutide as a long-term weight-management option that could influence adherence and coverage.

The new pill contains 25 mg of semaglutide, the same active ingredient as Wegovy and Ozempic, linking oral and injectable obesity and diabetes therapies.

By offering an affordable 1.5 mg option and stable pricing for higher doses, Novo Nordisk aims to broaden access for working adults and insured patients while addressing obesity treatment gaps.

Written using shared reports from

3 sources

Report issue

Analysis

Compare how each side frames the story — including which facts they emphasize or leave out.

Center-leaning sources identify mild editorial framing favorable to Wegovy’s launch: they frame the pill as an innovative, affordable option and emphasize availability, while relying on a single company source for validation and offering limited critical context about cost or broader obesity care.

How we categorize media bias